Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its ...

Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

Welcome to the Nanox fourth quarter 2024 earnings call. At this time, all participants are in a listen-only mode. After the ...

Scientists at the National Center for Supercomputing Applications and the University of Illinois College of Medicine Peoria (UICOMP) were authors of a research paper published in the Journal of ...

Thank you, operator, and good afternoon, everyone. Welcome to the Bionano fourth quarter 2024 financial results conference ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, ...

HAS Healthcare Advanced Synthesis SA ("HAS"), a leading international developer and producer of active pharmaceutical ingredients (APIs), high-potency active pharmaceutical ingredients (HPAPIs), and ...

BioLineRx Ltd. , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December ...

Holy Name Medical Center is deploying AI-powered hand hygiene stations in departments that treat the hospital’s most vulnerable patients.

The PGIM Jennison Growth Fund rose 6.5%, slightly underperforming the Russell 1000 Growth Index for Q4 2024. Click here to ...

The global US Biomarkers Market is expected to reach US$34.3 billion by 2029 from US$20.5 billion in 2024, at a CAGR of 10.8% during ...